PUMA BIOTECHNOLOGY, INC. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

PUMA BIOTECHNOLOGY, INC. reported Revenue From Contract With Customer Excluding Assessed Tax of $228.37 million for the year ending 2025.

  • PUMA BIOTECHNOLOGY, INC. showed a decrease of -0.9% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
  • This data is from PUMA BIOTECHNOLOGY, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 9 years of available data (2017 to 2025), PUMA BIOTECHNOLOGY, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 724.9%.
  • Historical annual values: Fiscal year 2025: $228.37 million | Fiscal year 2024: $230.47 million | Fiscal year 2023: $235.64 million | Fiscal year 2022: $228.03 million | Fiscal year 2021: $253.16 million | Fiscal year 2020: $225.11 million | Fiscal year 2019: $272.26 million | Fiscal year 2018: $250.99 million | Fiscal year 2017: $27.69 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: